Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005;45:1397-1405.
Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. Circulation. 2012;125:1501-1510.
Solomon SD, Zelenkofske S, McMurray JJ, et al; Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-2588.
Bardy GH, Lee KL, Mark DB, Poole JE, et al; HAT Investigators. Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med. 2008;358:1793-1804.
Bonow RO, Maurer G, Lee KL, et al; STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617-1625.
Dorian P, Hohnloser SH, Thorpe KE, et al. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT). Circulation. 2010;122:2645-2652.
Steinbeck G, Andresen D, Seidl K, et al; IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009; 361:1427-1436.
Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569-1575.
Shahian DM, O'Brien SM, Sheng S, et al. Predictors of long-term survival after coronary artery bypass grafting surgery: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT study). Circulation. 2012; 125:1491-1500.
Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2013;6:117-128.
Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol. 2010;56:194-203.

CME / CE

Early Risk of Mortality After Revascularization. What Do We Need To Do?

Authors: Rahul N. Doshi, MD; Mina K. Chung, MD; David E. Kandzari, MD; Eric E. Roselli, MD
CME / CE Released: 4/17/2013; Reviewed and Renewed: 9/2/2015
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/2/2016, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for electrophysiologists, interventional cardiologists, cardiac surgeons, clinical cardiologists, cardiology nurses and nurse practitioners, and other allied healthcare professionals.

The goal of this activity is to reinforce the need for risk stratification of patients undergoing revascularization so as to determine the appropriate need for therapy to prevent sudden cardiac death.

Upon completion of this activity, participants will be able to:

Examine the mortality risk and risk for sudden cardiac arrest after coronary revascularization
Evaluate measures to prevent sudden cardiac death in patients with compromised left ventricular ejection fraction after surgical and/or percutaneous revascularization

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator(s)

Rahul N. Doshi, MD, FACC

Assistant Professor of Medicine, University of California, Irvine; Director, Electrophysiology, UC Irvine Healthcare, St. Jude Medical Center, Fullerton, California

Disclosures

Disclosure: Rahul N. Doshi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: St. Jude Medical; Boston Scientific
Served as a speaker or a member of a speakers bureau for: St. Jude Medical; Boston Scientific

Dr Doshi does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Doshi does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Mina K. Chung, MD

Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Staff Cardiologist, Cardiac Electrophysiology and Pacing, The Robert and Suzanne Tomisch Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio

Disclosures

Disclosure: Mina K. Chung, MD, has disclosed no relevant financial relationships.

Dr Chung does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Chung does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

David E Kandzari, MD

Director, Interventional Cardiology; Chief Scientific Officer, Piedmont Heart Institute, Atlanta, Georgia

Disclosures

Disclosure: David E. Kandzari, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic; Boston Scientific; Micell Technologies, Inc.
Received grants for clinical research from: Abbott Vascular; Boston Scientific; Medtronic, Inc.

Dr Kandzari does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Kandzari does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Eric E. Roselli, MD

Staff Surgeon, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio

Disclosures

Disclosure: Eric E. Roselli, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic, Inc.
Served as a speaker or a member of a speakers bureau for: Medtronic, Inc.

Dr Roselli does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Roselli does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Ronald K. Miller, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Ronald K. Miller, PhD, has disclosed no relevant financial relationships.

Acute MI Steering Committee

Deepak L.Bhatt, MD, MPH

Chief of Cardiology, VA Boston Healthcare System; Senior Physician, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, Massachusetts

Disclosures

Disclosure: Deepak L. Bhatt, MD, MPH, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eisai Inc.; Ethicon, Inc.; Medtronic, Inc.; Sanofi; The Medicines Company; Medtronic, Inc.

Roberta C. Bogaev, MD

Schnitzler Cardiovascular Consultants, San Antonio, Texas

Disclosures

Disclosure: Roberta C. Bogaev, MD, has disclosed no relevant financial relationships.

Ted E. Feldman, MD

Director, Cardiac Catheterization Laboratory, Evanston Hospital, Evanston, Illinois

Disclosures

Disclosure: Ted E. Feldman, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Boston Scientific; Coherex Medical, Inc.; Edwards Lifesciences; Intervalve; Daiichi Sankyo, Inc.; Lilly USA, LLC; W.L. Gore & Associates, Inc.
Served as a speaker or a member of a speakers bureau for: Boston Scientific
Received grants for clinical research from: Abbott Laboratories; Boston Scientific; Edwards Lifesciences; St. Jude Medical; W.L. Gore & Associates, Inc.

Jagmeet P. Singh, MD, PhD

Associate Professor of Medicine, Harvard Medical School; Director, Cardiac Resynchronization Therapy Program and Holter and Noninvasive Electrophysiology Laboratory, Massachusetts General Hospital, Boston, Massachusetts

Disclosures

Disclosure: Jagmeet P. Singh, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Boston Scientific; Medtronic, Inc.; St. Jude Medical; Sorin Group; CardioInsight Technologies Inc.; Thoratec Corporation
Served as a speaker or a member of a speakers bureau for: BIOTRONIK; Boston Scientific; St. Jude Medical; Sorin Group
Received grants for clinical research from: BIOTRONIK; Boston Scientific; St. Jude Medical; Sorin Group; Medtronic, Inc.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Nurse Planner

Laurie E. Scudder, DNP, NP

Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC

Disclosures

Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For Nurses

Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

Accredited status does not imply endorsement by Medscape, LLC or ANCC of any commercial products discussed in conjunction with the educational activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / CE

Early Risk of Mortality After Revascularization. What Do We Need To Do?

Authors: Rahul N. Doshi, MD; Mina K. Chung, MD; David E. Kandzari, MD; Eric E. Roselli, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 4/17/2013; Reviewed and Renewed: 9/2/2015

Valid for credit through: 9/2/2016, 11:59 PM EST

processing....

This feature requires the newest version of Flash. You can download it here.

CME / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator(s)

Rahul N. Doshi, MD, FACC

Panelist(s)

Mina K. Chung, MD

David E Kandzari, MD

Eric E. Roselli, MD

Editor(s)

Ronald K. Miller, PhD

Acute MI Steering Committee

Deepak L.Bhatt, MD, MPH

Roberta C. Bogaev, MD

Ted E. Feldman, MD

Jagmeet P. Singh, MD, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

Nurse Planner

Laurie E. Scudder, DNP, NP

CME / CE

Early Risk of Mortality After Revascularization. What Do We Need To Do?

Target Audience and Goal Statement

Disclosures

Moderator(s)

Rahul N. Doshi, MD, FACC

Panelist(s)

Mina K. Chung, MD

David E Kandzari, MD

Eric E. Roselli, MD

Editor(s)

Ronald K. Miller, PhD

Acute MI Steering Committee

Deepak L.Bhatt, MD, MPH

Roberta C. Bogaev, MD

Ted E. Feldman, MD

Jagmeet P. Singh, MD, PhD

CME Reviewer(s)

Nafeez Zawahir, MD

Nurse Planner

Laurie E. Scudder, DNP, NP

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Early Risk of Mortality After Revascularization. What Do We Need To Do?